Schrödinger, a New York and Portland, OR-based maker of chemical-simulation software for drug development and research, has received a $10 million equity investment from Bill Gates through Cascade Investment, Gates’s private investment and holding company. The news was reported earlier today by the Wall Street Journal. The money will be used to support R&D projects to advance the state of the art in computer-aided drug design. Schrödinger (love the name) says its software “has been used by nearly every major pharmaceutical firm worldwide as well as hundreds of smaller firms and academic and government research laboratories.” The company, founded in 1990, also has offices in San Diego, Cambridge, MA, and New York.
By posting a comment, you agree to our terms and conditions.